North Carolina H567 ensures coverage for biomarker testing in health insurance and Medicaid.

North Carolina H567 mandates coverage for biomarker testing in health insurance and Medicaid for diagnosis, treatment, and monitoring of diseases. Biomarker testing includes analysis of tissue, blood, or other biospecimens. Insurers must disclose utilization review procedures and provide timely notifications for prior authorization requests. The bill also prohibits insurers from raising premiums or denying coverage based on genetic or biomarker information. Effective October 1, 2025, it applies to insurance contracts issued, renewed, or amended on or after that date.

North Carolina H567 ensures coverage for biomarker testing in health insurance and Medicaid.

North Carolina H567 mandates coverage for biomarker testing in health insurance and Medicaid for diagnosis, treatment, and monitoring of diseases. Biomarker testing includes analysis of tissue, blood, or other biospecimens. Insurers must disclose utilization review procedures and provide timely notifications for prior authorization requests. The bill also prohibits insurers from raising premiums or denying coverage based on genetic or biomarker information. Effective October 1, 2025, it applies to insurance contracts issued, renewed, or amended on or after that date.